Time filter

Source Type

News Article | April 28, 2017
Site: www.acnnewswire.com

Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and service markets, released its first quarterly report of 2017 on the night of 27 April, 2017. Data showed that During the Reporting Period, Shanghai Pharmaceuticals recorded operation revenue of RMB33.129 billion (Unit: RMB, following the same), representing an increase of 13.16% on a YOY basis. Net profit attributable to the equity holders of the listed company was RMB0.999 billion, representing a YOY increase of 12.37%. Net profit attributable to the equity holders of the listed company after deduction of non-recurring profit or loss was RMB0.939 billion, representing a YOY increase of 20.82%, achieved earnings per share RMB0.3717, earnings per share after deduction of non-recurring profit or loss was RMB0.3491. During the Reporting Period, the Company's net cash flow from operating activities was RMB0.376 billion, representing a YOY increase of 14.81%, fulfilling the budget target for the first quarter of 2017. In respect of pharmaceutical manufacturing business, Shanghai Pharmaceuticals achieved operating revenue of RMB3.794 billion in the first quarter of 2017, representing a YOY increase of 19.94% and a gross profit margin of 50.61%, representing a decrease of 0.34 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs was 14.14%, representing a YOY increase of 1.33 percentage points. In particular, sales revenue generated from its 60 key products increased by 15.07% on a YOY basis to RMB1.893 billion, accounting for 49.90% of the manufacturing sales. Average gross profit margin of key products was 69.82%, representing a YOY increase of 1.81 percentage points. Among the key products, there are 26 categories were expected to record sales revenue of more than RMB100 million over the year. In respect of pharmaceutical service, the Company achieved operating revenue of RMB29.485 billion in its pharmaceutical distribution business, representing a YOY increase of 12.93% and a gross profit margin of 6.15%, representing an increase of 0.16 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs of sales and administration was 2.64%, representing a YOY increase of 0.02 percentage point. During the Reporting Period, the operating revenue from the pharmaceutical retail business amounted to RMB1.280 billion, representing a YOY increase of 4.30% and a gross profit margin of 15.88%, representing a YOY increase of 0.34 percentage point. The operating profit margin after deducting the costs of sales and administration was 0.26%, representing a YOY decrease of 1.1 percentage points. The implementation of "two-invoice" policy will benefice large pharmaceutical distribution enterprises in expanding market share in the next three to five years. The Company's direct sales proportion in those provinces is thus expected to further enhance, which, in the long term, will strengthen the Company's profitability in distribution business. During the Reporting Period, Shanghai Pharmaceuticals Co., Ltd., the subsidiary of the Company, basically completed the layout of market in North Jiangsu through merger and acquisition of Xuzhou Pharmaceutical Co., Ltd. and Xuzhou Huaihai Pharmaceutical Co., Ltd.. The Company continued to manage the stock equity and enhance its competitiveness in Guangdong region through acquiring 31.593% equity of Guangzhou Z.S.Y Pharmaceutical Co., Ltd held by Guangzhou Zhongda Industry Group Co., Ltd Shanghai Pharmaceuticals also remarks that, as the integrated industrial company in the PRC that has leading positions in pharmaceutical manufacturing and business, the Company will ride on the industry reforms and actively grasp the industry trends to accelerate its transformation and development, and put more efforts in M&A activities, so as to maintain its leading status in the industry. Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2014-01-22

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]:^(1) is a cycloalkyl group and the like, R^(22) is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is -O- and the like, and R^(3) to R^(6) are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Shanghai Pharmaceuticals Holding CO. and Mitsubishi Group | Date: 2013-09-13

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R^(1 )is a cycloalkyl group or an alkyl,R^(22 )is an optionally substituted aryl and the like,R is a lower alkyl group,R^(3), R^(4), R^(5 )and R^(6 )are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl,or a pharmaceutically acceptable salt thereof.


Patent
Shanghai Pharmaceuticals Holding Co. and Mitsubishi Group | Date: 2012-03-15

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R^(1 )is a cycloalkyl group and the like, R^(22 )is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is O and the like, and R^(3 )to R^(6 )are the same or different and a hydrogen atom and the like;or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2016-01-12

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R^(1 )is a cycloalkyl group and the like, R^(22 )is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is O and the like, and R^(3 )to R^(6 )are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2015-10-21

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor.^(1) is a cycloalkyl group or an alkyl,R^(22) is an optionally substituted aryl and the like,R is a lower alkyl group,R^(3), R^(4), R^(5) and R^(6) are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl,or a pharmaceutically acceptable salt thereof.


Patent
Changzhou Pharmaceutical Factory and Shanghai Pharmaceuticals Holding Co. | Date: 2013-06-21

The present invention relates to a compound solid preparation and the preparation method therefor and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared by preparing wet valsartan particles from a mixture obtained by mixing valsartan and a pharmaceutic adjuvant with an ethanol aqueous solution as a wetting agent and drying the wet valsartan particles. The amlodipine premix is prepared by mixing amlodipine and a pharmaceutic adjuvant. The valsartan-amlodipine compound solid preparation according to the present invention and the preparation method thereof can prevent the two main ingredients, amlodipine and valsartan, from interfering each other, and the preparation method is relatively simple and suitable for large-scale industrial production.


News Article | October 28, 2016
Site: www.acnnewswire.com

Results Achieved Steady Growth with Extension and Expansion as Driving Engine Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and service markets, today released its third quarterly report of 2016. According to the data, from January to September 2016, Shanghai Pharmaceuticals' operating revenue was RMB90.517 billion (Unit: RMB, following the same), representing an increase of 14.52% on a YOY basis. Net profit attributable to the equity holders of the listed company was RMB2.457 billion, representing a YOY increase of 12.78%. Net profit attributable to the equity holders of the listed company after deduction of non-recurring profit or loss was RMB2.283 billion, representing a YOY increase of 11.13%, fulfilling earnings per share RMB0.9138, earnings per share after deduction of non-recurring profit or loss was RMB0.8490. From January to September 2016, the Company's net cash flow from operating activities was RMB1.310 billion, fulfilling the budget target for the third quarter of 2016. For the aspect of pharmaceutical research and development, Shanghai Pharmaceuticals underwent systemization in research and development products and progressed smoothly in research projects in the third quarter of 2016. The Company increased 9 clinical trial approvals for five kinds of medicines, namely recombinant anti-CD20 humanized monoclonal antibody injection, Lacosamide API and Tablet, Ferric carboxymaltose API and Injection, sugammadex API and Injection, rabeprazole sodium, 1 approval for production of thyoidin as well as 2 clinical trial approvals for injectable recombinant anti-HER2 humanized monoclonal antibody composition and beclometasone dipropionate aerosol. In respect of the pharmaceutical manufacturing business, from January to September 2016, Shanghai Pharmaceuticals achieved operating revenue of 9.396 billion in its pharmaceutical manufacturing business, representing a YOY increase of 5.76% and a gross profit margin of 52.21%, representing an increase of 2.48 percentage points as compared with the corresponding period of last year. The operating profit margin after deducting the costs of sales and administration was 13.50%, representing an increase of 0.71 percentage point as compared with the corresponding period of last year. In particular, sales revenue generated from its 60 key products increased by 6.98% on a YOY basis to RMB5.185 billion, accounting for 55.18% of the manufacturing sales. Average gross profit margin of key products was 69.11%, representing an increase of 1.72 percentage points as compared with the corresponding period of last year. Among the key products, there are 36 categories, the growth of which are higher than or equal to the same categories of IMS Health Inc.. 25 major categories are expected to record sales revenue of more than RMB100 million over the year. In respect of pharmaceutical services business, from January to September 2016, Shanghai Pharmaceuticals achieved operating revenue of RMB81.302 billion in its pharmaceutical distribution business, representing a YOY increase of 16.44%, achieved a steady growth rate higher than the industry's average. The gross profit margin was 6.00%, representing an increase of 0.08 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs of sales and administration was 2.64%, representing a decrease of 0.09 percentage point as compared with the corresponding period of last year. The operating revenue from the pharmaceutical retail business amounted to RMB3.765 billion, representing a YOY increase of 7.42% and a gross profit margin of 15.44%, representing a decrease of 0.04 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs of sales and administration was 1.27%, representing a decrease of 0.04 percentage point as compared with the corresponding period of last year. In respect of capital expansion, with purpose of tapping into health care industry and accelerating the progress of globalization, Shanghai Pharmaceuticals decided to acquire 60% equity of Vitaco Holdings Limited, a company listed on the ASX, with the consideration of RMB938 million by cash (for details, please refer to the Company's announcement). For expanding into the northeast market, enhancing the competitiveness and facilitating the business network layout thereof, the Company determined to acquire 60% equity interests of Harbin Yangpuyuhua Pharmaceutical Distribution Co., Ltd. by SPH Keyuan Xinhai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company. For the implementation of the business network layout in the southwest market of Shanghai Pharmaceuticals, the Company determined to acquire 70% equity of Yunnan Shanghai Pharmaceuticals Co., Ltd. by Shanghai Pharmaceutical Distribution Co., Ltd., a wholly-owned subsidiary of the Company. In response to the State's efforts to strongly develop traditional Chinese medicine and with an aim to offer better health care services for the public, Shanghai Traditional Chinese Medicine Co., Ltd., a wholly-owned subsidiary of the Company, based on the strategic position of "adhering to the strategy of development of the whole industrial chain of Chinese traditional medicine and priority on quality", established Leishi Traditional Chinese Medicine Center as a step entering into the Chinese traditional medicine healthcare investment and service areas, and, by the combination of famous doctors and renowned traditional Chinese medicine and decoction pieces brands, namely the combination of "skillful doctors and good medicine", created a new model for health service with the integration of the treatment and health preserving. Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Patent
Zhejiang University and Shanghai Pharmaceuticals Holding Co. | Date: 2012-07-27

Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.


News Article | October 31, 2016
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 Prescription Drug joint venture with a subsidiary of Shanghai Pharmaceuticals Holding Co., Limited (“Shanghai Pharma”), has today received US$59.5 million from the Shanghai government under the terms of their December 2015 land compensation agreement (the “Compensation Agreement”). As announced on December 9, 2015, SHPL and th

Loading Shanghai Pharmaceuticals Holding Co. collaborators
Loading Shanghai Pharmaceuticals Holding Co. collaborators